Ipragliflozin
Composition
Contains Ipragliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor.
Indications
Used to improve glycemic control in adults with type 2 diabetes mellitus, often as adjunct to diet and exercise.
Side effects
Urinary tract infections, genital infections, increased urination, dehydration, dizziness.
Precautions
Monitor for signs of volume depletion and infections; use cautiously in renal impairment.
Contraindications
Severe renal impairment, end-stage renal disease, hypersensitivity to ipragliflozin.
Dosage and administration
Typical dose: 50 mg orally once daily, may be adjusted per clinical response.
Countries
Available Forms
Oral tablets.